SEC Opens Probe of Sequenom Research
San Diego’s Sequenom, which postponed release of its prenatal test for Down syndrome, disclosed in a filing that the Securities and Exchange Commision has initated an investigation into the company’s mishandling of data supporting the genetic test. The company says it received written notification of the probe from the SEC on June 29. The value of Sequenom’s shares plunged by 70 percent on April 29, when the medical diagnostics company said it had found inconsistencies in research and development data for its SEQureDx technology. The company says it plans to cooperate with the SEC and its own internal investigation is continuing.